Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Nov 15;98(10):2364–2372. doi: 10.1172/JCI119049

Systemic hypertension induced by hepatic overexpression of human preproendothelin-1 in rats.

V Niranjan 1, S Télémaque 1, D deWit 1, R D Gerard 1, M Yanagisawa 1
PMCID: PMC507688  PMID: 8941655

Abstract

Endothelin-1 (ET-1) has been implicated in the regulation of vascular tone in various pathological conditions. To examine the effect of in vivo overexpression of the peptide in rats, we prepared recombinant adenovirus stocks encoding the human preproET-1 cDNA (Ad.ET-1) or Escherichia coli lacZ (Ad.betaGal), each driven by cytomegalovirus early promoter. Ad.ET-1 or Ad.betaGal was injected into the caudal vein of rats and the animals were studied under anesthesia 96 h later. Hepatic overexpression of the virus-derived human ET-1 mRNA was accompanied by a 13-fold elevation of liver ET-1 content in the Ad.ET-1 group. Circulating plasma ET-1 levels in the Ad.ET-1 group were sixfold higher than those in the Ad.betaGal group. Mean arterial blood pressure was increased by 28 mmHg in the Ad.ET-1 group as compared with the Ad.betaGal group. In the Ad.ET-1 group, intravenous infusion of the ET(A) receptor antagonist FR 139317 reduced the blood pressure to levels seen in the Ad.betaGal group, whereas the same antagonist did not significantly alter the blood pressure in the Ad.betaGal group. Intravenous infusion of the ET(B) receptor antagonist BQ-788 caused a small but significant increase in blood pressure in both groups. These findings demonstrate that endogenous overexpression of preproET-1, accompanied by an elevation of plasma ET-1 concentrations to the levels seen in pathophysiological states, can cause systemic hypertension through the activation of the ETA receptor.

Full Text

The Full Text of this article is available as a PDF (232.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allcock G. H., Warner T. D., Vane J. R. Roles of endothelin receptors in the regional and systemic vascular responses to ET-1 in the anaesthetized ganglion-blocked rat: use of selective antagonists. Br J Pharmacol. 1995 Nov;116(5):2482–2486. doi: 10.1111/j.1476-5381.1995.tb15099.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990 Dec 20;348(6303):730–732. doi: 10.1038/348730a0. [DOI] [PubMed] [Google Scholar]
  3. Bajocchi G., Feldman S. H., Crystal R. G., Mastrangeli A. Direct in vivo gene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectors. Nat Genet. 1993 Mar;3(3):229–234. doi: 10.1038/ng0393-229. [DOI] [PubMed] [Google Scholar]
  4. Clozel M., Breu V., Burri K., Cassal J. M., Fischli W., Gray G. A., Hirth G., Löffler B. M., Müller M., Neidhart W. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature. 1993 Oct 21;365(6448):759–761. doi: 10.1038/365759a0. [DOI] [PubMed] [Google Scholar]
  5. Corder R., Vane J. R. Radioimmunoassay evidence that the pressor effect of big endothelin-1 is due to local conversion to endothelin-1. Biochem Pharmacol. 1995 Jan 31;49(3):375–380. doi: 10.1016/0006-2952(94)00425-l. [DOI] [PubMed] [Google Scholar]
  6. De Lombaert S., Ghai R. D., Jeng A. Y., Trapani A. J., Webb R. L. Pharmacological profile of a non-peptidic dual inhibitor of neutral endopeptidase 24.11 and endothelin-converting enzyme. Biochem Biophys Res Commun. 1994 Oct 14;204(1):407–412. doi: 10.1006/bbrc.1994.2473. [DOI] [PubMed] [Google Scholar]
  7. Deng A. Y., Dene H., Pravenec M., Rapp J. P. Genetic mapping of two new blood pressure quantitative trait loci in the rat by genotyping endothelin system genes. J Clin Invest. 1994 Jun;93(6):2701–2709. doi: 10.1172/JCI117284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Douglas S. A., Gellai M., Ezekiel M., Ohlstein E. H. BQ-123, a selective endothelin subtype A-receptor antagonist, lowers blood pressure in different rat models of hypertension. J Hypertens. 1994 May;12(5):561–567. [PubMed] [Google Scholar]
  9. Druml W., Steltzer H., Waldhäusl W., Lenz K., Hammerle A., Vierhapper H., Gasic S., Wagner O. F. Endothelin-1 in adult respiratory distress syndrome. Am Rev Respir Dis. 1993 Nov;148(5):1169–1173. doi: 10.1164/ajrccm/148.5.1169. [DOI] [PubMed] [Google Scholar]
  10. Fukuroda T., Fujikawa T., Ozaki S., Ishikawa K., Yano M., Nishikibe M. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun. 1994 Mar 30;199(3):1461–1465. doi: 10.1006/bbrc.1994.1395. [DOI] [PubMed] [Google Scholar]
  11. Gardiner S. M., March J. E., Kemp P. A., Mullins J. J., Bennett T. Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats. Br J Pharmacol. 1995 Oct;116(4):2237–2244. doi: 10.1111/j.1476-5381.1995.tb15059.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gratton J. P., Maurice M. C., Rae G. A., D'Orléans-Juste P. Pharmacological properties of endothelins and big endothelins in ketamine/xylazine or urethane anesthetized rats. Am J Hypertens. 1995 Nov;8(11):1121–1127. doi: 10.1016/0895-7061(95)00227-G. [DOI] [PubMed] [Google Scholar]
  13. Haynes W. G., Ferro C. J., O'Kane K. P., Somerville D., Lomax C. C., Webb D. J. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation. 1996 May 15;93(10):1860–1870. doi: 10.1161/01.cir.93.10.1860. [DOI] [PubMed] [Google Scholar]
  14. Hemsén A., Ahlborg G., Ottosson-Seeberger A., Lundberg J. M. Metabolism of Big endothelin-1 (1-38) and (22-38) in the human circulation in relation to production of endothelin-1 (1-21). Regul Pept. 1995 Feb 14;55(3):287–297. doi: 10.1016/0167-0115(94)00119-i. [DOI] [PubMed] [Google Scholar]
  15. Herz J., Gerard R. D. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2812–2816. doi: 10.1073/pnas.90.7.2812. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ishibashi M., Saito K., Watanobe K., Uesugi S., Furue H., Yamaji T. Plasma endothelin-1 levels in patients with disseminated intravascular coagulation. N Engl J Med. 1991 May 23;324(21):1516–1517. doi: 10.1056/NEJM199105233242121. [DOI] [PubMed] [Google Scholar]
  17. Ishikawa K., Ihara M., Noguchi K., Mase T., Mino N., Saeki T., Fukuroda T., Fukami T., Ozaki S., Nagase T. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci U S A. 1994 May 24;91(11):4892–4896. doi: 10.1073/pnas.91.11.4892. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Itoh Y., Yanagisawa M., Ohkubo S., Kimura C., Kosaka T., Inoue A., Ishida N., Mitsui Y., Onda H., Fujino M. Cloning and sequence analysis of cDNA encoding the precursor of a human endothelium-derived vasoconstrictor peptide, endothelin: identity of human and porcine endothelin. FEBS Lett. 1988 Apr 25;231(2):440–444. doi: 10.1016/0014-5793(88)80867-6. [DOI] [PubMed] [Google Scholar]
  19. Kamoi K., Sudo N., Ishibashi M., Yamaji T. Plasma endothelin-1 levels in patients with pregnancy-induced hypertension. N Engl J Med. 1990 Nov 22;323(21):1486–1487. doi: 10.1056/NEJM199011223232113. [DOI] [PubMed] [Google Scholar]
  20. Kochanek S., Clemens P. R., Mitani K., Chen H. H., Chan S., Caskey C. T. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5731–5736. doi: 10.1073/pnas.93.12.5731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kohno M., Murakawa K., Horio T., Yokokawa K., Yasunari K., Fukui T., Takeda T. Plasma immunoreactive endothelin-1 in experimental malignant hypertension. Hypertension. 1991 Jul;18(1):93–100. doi: 10.1161/01.hyp.18.1.93. [DOI] [PubMed] [Google Scholar]
  22. Koller J., Mair P., Wieser C., Pomaroli A., Puschendorf B., Herold M. Endothelin and big endothelin concentrations in injured patients. N Engl J Med. 1991 Nov 21;325(21):1518–1518. doi: 10.1056/NEJM199111213252118. [DOI] [PubMed] [Google Scholar]
  23. Koseki C., Imai M., Hirata Y., Yanagisawa M., Masaki T. Autoradiographic distribution in rat tissues of binding sites for endothelin: a neuropeptide? Am J Physiol. 1989 Apr;256(4 Pt 2):R858–R866. doi: 10.1152/ajpregu.1989.256.4.R858. [DOI] [PubMed] [Google Scholar]
  24. Kurihara Y., Kurihara H., Suzuki H., Kodama T., Maemura K., Nagai R., Oda H., Kuwaki T., Cao W. H., Kamada N. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature. 1994 Apr 21;368(6473):703–710. doi: 10.1038/368703a0. [DOI] [PubMed] [Google Scholar]
  25. Kuwaki T., Cao W. H., Kurihara Y., Kurihara H., Ling G. Y., Onodera M., Ju K. H., Yazaki Y., Kumada M. Impaired ventilatory responses to hypoxia and hypercapnia in mutant mice deficient in endothelin-1. Am J Physiol. 1996 Jun;270(6 Pt 2):R1279–R1286. doi: 10.1152/ajpregu.1996.270.6.R1279. [DOI] [PubMed] [Google Scholar]
  26. Lerman A., Edwards B. S., Hallett J. W., Heublein D. M., Sandberg S. M., Burnett J. C., Jr Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med. 1991 Oct 3;325(14):997–1001. doi: 10.1056/NEJM199110033251404. [DOI] [PubMed] [Google Scholar]
  27. Lerman A., Hildebrand F. L., Jr, Aarhus L. L., Burnett J. C., Jr Endothelin has biological actions at pathophysiological concentrations. Circulation. 1991 May;83(5):1808–1814. doi: 10.1161/01.cir.83.5.1808. [DOI] [PubMed] [Google Scholar]
  28. McMahon E. G., Palomo M. A., Moore W. M. Phosphoramidon blocks the pressor activity of big endothelin[1-39] and lowers blood pressure in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1991;17 (Suppl 7):S29–S33. doi: 10.1097/00005344-199100177-00009. [DOI] [PubMed] [Google Scholar]
  29. Nishikibe M., Tsuchida S., Okada M., Fukuroda T., Shimamoto K., Yano M., Ishikawa K., Ikemoto F. Antihypertensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive model. Life Sci. 1993;52(8):717–724. doi: 10.1016/0024-3205(93)90233-s. [DOI] [PubMed] [Google Scholar]
  30. Ohlstein E. H., Douglas S. A., Ezekiel M., Gellai M. Antihypertensive effects of the endothelin receptor antagonist BQ-123 in conscious spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1993;22 (Suppl 8):S321–S324. doi: 10.1097/00005344-199322008-00084. [DOI] [PubMed] [Google Scholar]
  31. Ohlstein E. H., Nambi P., Douglas S. A., Edwards R. M., Gellai M., Lago A., Leber J. D., Cousins R. D., Gao A., Frazee J. S. SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8052–8056. doi: 10.1073/pnas.91.17.8052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Ohno A., Naruse M., Kato S., Hosaka M., Naruse K., Demura H., Sugino N. Endothelin-specific antibodies decrease blood pressure and increase glomerular filtration rate and renal plasma flow in spontaneously hypertensive rats. J Hypertens. 1992 Aug;10(8):781–785. [PubMed] [Google Scholar]
  33. Oishi R., Nonoguchi H., Tomita K., Marumo F. Endothelin-1 inhibits AVP-stimulated osmotic water permeability in rat inner medullary collecting duct. Am J Physiol. 1991 Dec;261(6 Pt 2):F951–F956. doi: 10.1152/ajprenal.1991.261.6.F951. [DOI] [PubMed] [Google Scholar]
  34. Rubanyi G. M., Polokoff M. A. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev. 1994 Sep;46(3):325–415. [PubMed] [Google Scholar]
  35. Saito Y., Nakao K., Mukoyama M., Imura H. Increased plasma endothelin level in patients with essential hypertension. N Engl J Med. 1990 Jan 18;322(3):205–205. doi: 10.1056/nejm199001183220315. [DOI] [PubMed] [Google Scholar]
  36. Sakurai T., Yanagisawa M., Takuwa Y., Miyazaki H., Kimura S., Goto K., Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990 Dec 20;348(6303):732–735. doi: 10.1038/348732a0. [DOI] [PubMed] [Google Scholar]
  37. Schiffrin E. L., Larivière R., Li J. S., Sventek P. Enhanced expression of the endothelin-1 gene in blood vessels of DOCA-salt hypertensive rats: correlation with vascular structure. J Vasc Res. 1996 May-Jun;33(3):235–248. doi: 10.1159/000159151. [DOI] [PubMed] [Google Scholar]
  38. Schiffrin E. L., Thibault G. Plasma endothelin in human essential hypertension. Am J Hypertens. 1991 Apr;4(4 Pt 1):303–308. doi: 10.1093/ajh/4.4.303. [DOI] [PubMed] [Google Scholar]
  39. Shennib H., Serrick C., Saleh D., Reis A., Stewart D. J., Giaid A. Plasma endothelin-1 levels in human lung transplant recipients. J Cardiovasc Pharmacol. 1995;26 (Suppl 3):S516–S518. [PubMed] [Google Scholar]
  40. Shichiri M., Hirata Y., Ando K., Emori T., Ohta K., Kimoto S., Ogura M., Inoue A., Marumo F. Plasma endothelin levels in hypertension and chronic renal failure. Hypertension. 1990 May;15(5):493–496. doi: 10.1161/01.hyp.15.5.493. [DOI] [PubMed] [Google Scholar]
  41. Simonson M. S., Dunn M. J. Endothelin peptides and the kidney. Annu Rev Physiol. 1993;55:249–265. doi: 10.1146/annurev.ph.55.030193.001341. [DOI] [PubMed] [Google Scholar]
  42. Sogabe K., Nirei H., Shoubo M., Nomoto A., Ao S., Notsu Y., Ono T. Pharmacological profile of FR139317, a novel, potent endothelin ETA receptor antagonist. J Pharmacol Exp Ther. 1993 Mar;264(3):1040–1046. [PubMed] [Google Scholar]
  43. Stein P. D., Hunt J. T., Floyd D. M., Moreland S., Dickinson K. E., Mitchell C., Liu E. C., Webb M. L., Murugesan N., Dickey J. The discovery of sulfonamide endothelin antagonists and the development of the orally active ETA antagonist 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulf onamide. J Med Chem. 1994 Feb 4;37(3):329–331. doi: 10.1021/jm00029a001. [DOI] [PubMed] [Google Scholar]
  44. Stewart D. J., Cernacek P., Costello K. B., Rouleau J. L. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation. 1992 Feb;85(2):510–517. doi: 10.1161/01.cir.85.2.510. [DOI] [PubMed] [Google Scholar]
  45. Stewart D. J., Kubac G., Costello K. B., Cernacek P. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol. 1991 Jul;18(1):38–43. doi: 10.1016/s0735-1097(10)80214-1. [DOI] [PubMed] [Google Scholar]
  46. Sudo N., Kamoi K., Ishibashi M., Yamaji T. Plasma endothelin-1 and big endothelin-1 levels in women with pre-eclampsia. Acta Endocrinol (Copenh) 1993 Aug;129(2):114–120. doi: 10.1530/acta.0.1290114. [DOI] [PubMed] [Google Scholar]
  47. Suzuki N., Matsumoto H., Miyauchi T., Kitada C., Tsuda M., Goto K., Masaki T., Fujino M. Sandwich-enzyme immunoassays for endothelin family peptides. J Cardiovasc Pharmacol. 1991;17 (Suppl 7):S420–S422. doi: 10.1097/00005344-199100177-00119. [DOI] [PubMed] [Google Scholar]
  48. Suzuki N., Miyauchi T., Tomobe Y., Matsumoto H., Goto K., Masaki T., Fujino M. Plasma concentrations of endothelin-1 in spontaneously hypertensive rats and DOCA-salt hypertensive rats. Biochem Biophys Res Commun. 1990 Mar 30;167(3):941–947. doi: 10.1016/0006-291x(90)90614-s. [DOI] [PubMed] [Google Scholar]
  49. Thompson A., Valeri C. R., Lieberthal W. Endothelin receptor A blockade alters hemodynamic response to nitric oxide inhibition in rats. Am J Physiol. 1995 Aug;269(2 Pt 2):H743–H748. doi: 10.1152/ajpheart.1995.269.2.H743. [DOI] [PubMed] [Google Scholar]
  50. Tomita K., Nonoguchi H., Marumo F. Effects of endothelin on peptide-dependent cyclic adenosine monophosphate accumulation along the nephron segments of the rat. J Clin Invest. 1990 Jun;85(6):2014–2018. doi: 10.1172/JCI114667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Tomita K., Ujiie K., Nakanishi T., Tomura S., Matsuda O., Ando K., Shichiri M., Hirata Y., Marumo F. Plasma endothelin levels in patients with acute renal failure. N Engl J Med. 1989 Oct 19;321(16):1127–1127. doi: 10.1056/NEJM198910193211615. [DOI] [PubMed] [Google Scholar]
  52. Watanabe T., Suzuki N., Shimamoto N., Fujino M., Imada A. Contribution of endogenous endothelin to the extension of myocardial infarct size in rats. Circ Res. 1991 Aug;69(2):370–377. doi: 10.1161/01.res.69.2.370. [DOI] [PubMed] [Google Scholar]
  53. Widimsky J., Jr, Horky K., Dvorakova J. Plasma endothelin-1,2 levels in mild and severe hypertension. J Hypertens Suppl. 1991 Dec;9(6):S194–S195. [PubMed] [Google Scholar]
  54. Wilkins F. C., Jr, Alberola A., Mizelle H. L., Opgenorth T. J., Granger J. P. Systemic hemodynamics and renal function during long-term pathophysiological increases in circulating endothelin. Am J Physiol. 1995 Feb;268(2 Pt 2):R375–R381. doi: 10.1152/ajpregu.1995.268.2.R375. [DOI] [PubMed] [Google Scholar]
  55. Winn M., von Geldern T. W., Opgenorth T. J., Jae H. S., Tasker A. S., Boyd S. A., Kester J. A., Mantei R. A., Bal R., Sorensen B. K. 2,4-Diarylpyrrolidine-3-carboxylic acids--potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722. J Med Chem. 1996 Mar 1;39(5):1039–1048. doi: 10.1021/jm9505369. [DOI] [PubMed] [Google Scholar]
  56. Xu D., Emoto N., Giaid A., Slaughter C., Kaw S., deWit D., Yanagisawa M. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell. 1994 Aug 12;78(3):473–485. doi: 10.1016/0092-8674(94)90425-1. [DOI] [PubMed] [Google Scholar]
  57. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988 Mar 31;332(6163):411–415. doi: 10.1038/332411a0. [DOI] [PubMed] [Google Scholar]
  58. Yanagisawa M. The endothelin system. A new target for therapeutic intervention. Circulation. 1994 Mar;89(3):1320–1322. doi: 10.1161/01.cir.89.3.1320. [DOI] [PubMed] [Google Scholar]
  59. Yasujima M., Abe K., Kanazawa M., Yoshida K., Sato M., Takeuchi K., Tsunoda K., Kudo K., Kohzuki M., Omata K. Chronic effects of synthetic endothelin on blood pressure and sodium excretion in rats. Am J Hypertens. 1990 Aug;3(8 Pt 1):635–637. doi: 10.1093/ajh/3.8.635. [DOI] [PubMed] [Google Scholar]
  60. Yokokawa K., Tahara H., Kohno M., Murakawa K., Yasunari K., Nakagawa K., Hamada T., Otani S., Yanagisawa M., Takeda T. Hypertension associated with endothelin-secreting malignant hemangioendothelioma. Ann Intern Med. 1991 Feb 1;114(3):213–215. doi: 10.7326/0003-4819-114-3-213. [DOI] [PubMed] [Google Scholar]
  61. de Nucci G., Thomas R., D'Orleans-Juste P., Antunes E., Walder C., Warner T. D., Vane J. R. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A. 1988 Dec;85(24):9797–9800. doi: 10.1073/pnas.85.24.9797. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES